These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30224273)

  • 41. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
    Kinoshita T; Ishii G; Matsumura Y; Shiozawa T; Aokage K; Hishida T; Yoshida J; Nagai K
    Pathol Int; 2012 Nov; 62(11):754-7. PubMed ID: 23121607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
    Bovolato P; Casadio C; Billè A; Ardissone F; Santambrogio L; Ratto GB; Garofalo G; Bedini AV; Garassino M; Porcu L; Torri V; Pastorino U
    J Thorac Oncol; 2014 Mar; 9(3):390-6. PubMed ID: 24518090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
    Abdel-Rahman O
    Strahlenther Onkol; 2017 Apr; 193(4):276-284. PubMed ID: 28044200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Sharma S; Shabason J; Culligan MJ; Grover S; Friedberg JS; Simone CB
    J Thorac Oncol; 2017 Nov; 12(11):1704-1714. PubMed ID: 28843362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
    Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
    Yang CJ; Yan BW; Meyerhoff RR; Saud SM; Gulack BC; Speicher PJ; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
    Clin Lung Cancer; 2016 Sep; 17(5):419-426. PubMed ID: 27236386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
    Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
    Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
    J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study.
    Marulli G; Breda C; Fontana P; Ratto GB; Leoncini G; Alloisio M; Infante M; Luzzi L; Paladini P; Oliaro A; Ruffini E; Benvenuti MR; Pariscenti G; Spaggiari L; Casiraghi M; Rusca M; Carbognani P; Ampollini L; Facciolo F; Leuzzi G; Mucilli F; Camplese P; Romanello P; Perissinotto E; Rea F
    Eur J Cardiothorac Surg; 2017 Jul; 52(1):63-69. PubMed ID: 28419212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
    Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
    PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
    de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE
    Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.
    Lewis GD; Dalwadi SM; Farach A; Brian Butler E; Teh BS
    Ann Surg Oncol; 2019 Jun; 26(6):1879-1885. PubMed ID: 30798447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.